136
Participants
Start Date
October 30, 2009
Primary Completion Date
December 31, 2010
Study Completion Date
January 31, 2011
Tapentadol Prolonged Release
"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
BE004, Bruges
BE003, Charleroi
BE002, Edegem
BE001, Liège
CZ001, Brno
FR004, Thionville
FR001, Toulouse
DE005, Albstadt
DE001, Berlin
DE003, Berlin
DE006, Kiel
DE004, Leipzig
DE008, Leipzig
DE007, Stuttgart
NL002, Alkmaar
NL004, Doetinchem
NL003, Eindhoven
NL001, Tiel
PL002, Krakow
PL001, Poznan
ES006, Cadiz
ES001, Granada
ES003, Málaga
ES004, Seville
ES005, Valencia
CH001, Basel
CH002, Sankt Gallen
Lead Sponsor
Grünenthal GmbH
INDUSTRY